Hepatitis C Marketing: Applying Primary Care Tactics To Specialty Products
By
Joseph Haas / Email the Author / IN VIVO June 2011, Vol. 29, No. 6
Around The Industry / Word Count: 1403 / Article # 2011800102
Executive Summary
The Food and Drug Administration's back-to-back approvals of Hepatitis C therapies from Merck & Co. and Vertex Pharmaceuticals set the stage for a specialty-focused marketing battle the likes of which the biopharma industry hasn't seen in years.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.